


 Cite this: *RSC Adv.*, 2025, 15, 19561

Discovery of potential small molecule inhibitors against β -hCG: an *in silico* study with *in vitro* validation†

 Shreya Sara Ittycheria,^{ab} Krishnankutty Chandrika Sivakumar,^a Dipyaman Patra,^{‡a} Bhavana Ramachandran,^a R. L. Neetha,^{ac} Arathy V. Warriar,^{ac} M. A. Aiswariya,^{ad} S. Kaviya,^{ad} Pankaj Suman,^e Nagarjun Narayanaswamy^a and Priya Srinivas^{id} *^{ad}

Previous *in vitro* and *in vivo* studies have shown an association between BRCA1-defective cancers and the expression of β -hCG, where accelerated tumor progression has been observed in the presence of β -hCG due to its binding to and phosphorylation of TGF β R-II. Given the absence of reported small molecule inhibitors against β -hCG, the present study endeavours to identify the interacting residues of β -hCG with TGF β R-II. Through virtual screening, molecular docking and dynamic simulation studies, the investigation identified six potential small molecule inhibitors, namely, cefotetan, 2',7'-dichlorofluorescein (DCF), 2',7'-difluorofluorescein (DFF), F6658-4634, F0922-0590 and F0385-0029. Notably, all inhibitors exhibited interacting residues on β -hCG that coincided with the site to which it binds to TGF β R-II. Further *in vitro* MTT assays showed a reduction in proliferation in various cell lines, including the cell line developed in our laboratory, which was induced to have BRCA1 promoter hypermethylation using modified CRISPR technology. Binding studies such as Microscale Thermophoresis (MST) and Isothermal Titration Calorimetry (ITC) exhibited the binding of cefotetan to hCG, which could be indicative of the selective cytotoxic effect of cefotetan in β -hCG secreting breast cancer cell lines. The results indicate selective inhibition by these potential inhibitors in BRCA1-defective breast cancer cell lines, with cefotetan being the best among all with an IC₅₀ of 32 μ M. This is the first study to report the anticancer activity of cefotetan, an FDA-approved drug used to treat bacterial infections, and this drug could be repurposed as a targeted therapeutic against β -hCG expressing cancers. Findings of this study hold significant implications for developing potential therapeutic interventions, which target β -hCG in the context of BRCA1-defective breast cancers, aligning with the broader goal of advancing precision medicine in oncology.

 Received 9th December 2024
 Accepted 20th February 2025

DOI: 10.1039/d4ra08663e

rsc.li/rsc-advances

1 Introduction

Breast cancer (BC) represents a significant global health concern, accounting for 23.8% of the global cancer burden and 15.4% of cancer-related deaths among women worldwide.^{1,2} Of note, the majority of BC cases occur sporadically, often associated with hypermethylation in the BRCA1 promoter and

culminating in triple-negative breast cancers (TNBCs) in approximately 40% of cases.³ The presence of the beta subunit of human chorionic gonadotropin (hCG), a glycoprotein secreted by syncytiotrophoblasts within the placental endometrium, has been detected in some cancers.⁴ Extensive *in vitro* and *in vivo* investigations conducted in our laboratory have revealed the expression of β -hCG in BRCA1-defective cancers. The role of β -hCG in accelerating tumor progression and enhancing aggressiveness in BRCA1-defective cancer cells through the Smad signalling pathway indicates a direct relation between serum β -hCG levels and the disease progression in women with breast malignancies.¹⁰ β -hCG as a monomer (and not α -hCG) is reported to be expressed by various cancer cells and is considered stable; even free β -hCG is secreted through urine in pregnant women.

Human chorionic gonadotropin (hCG) is a heterodimeric molecule consisting of α and β subunits, with the β -subunit spanning 145 amino acids, thus setting hCG apart from other glycoproteins. The α subunit of hCG is common to FSH, LH and

^aCancer Research Program, BRIC-Rajiv Gandhi Centre for Biotechnology, Thycaud, Thiruvananthapuram 695014, Kerala, India. E-mail: priyasrinivas@rgcb.res.in; Tel: +91-471-2529495

^bManipal Academy of Higher Education (MAHE), Manipal 576104, India

^cResearch Centre, University of Kerala, Thiruvananthapuram, Kerala, India

^dDBT-Regional Centre for Biotechnology (RCB), Faridabad 121001, Haryana, India

^eNational Institute of Animal Biotechnology, Gachibowli, Hyderabad, Telangana 500032, India

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra08663e>

‡ Current address: Department of Immunology, University of Pittsburgh, PA 15213, USA.



TSH, but the β subunit is unique to hCG, which is secreted by certain cancers, thus setting hCG apart from other glycoproteins.¹¹ In the realm of cancer therapeutics, the prospect of targeting the β -subunit of hCG holds potential by impeding its interaction with TGF β R-II, consequently mitigating tumor progression through the Smad signalling pathway in cancers expressing β -hCG. While the conventional approach of targeting the receptor, specifically TGF β R-II in BRCA1-defective cancers, may appear more intuitive, it is imperative to recognize the multifaceted role of TGF β signalling. This encompasses pivotal biological pathways in both adult organisms and developing embryos, regulating cell growth, differentiation, migration, apoptosis, cellular homeostasis and other cellular functions.¹² Disruption of the TGF β signalling pathway, including inhibition of TGF β R-II, has the potential to perturb these essential cellular processes.

The atypical expression of β -hCG offers a viable therapeutic strategy in BRCA1-defective breast cancers. This approach not only streamlines the drug discovery process but also circumvents the long timelines and exorbitant costs associated with traditional drug development endeavours.

Drawing parallels with a study on the design of inhibitors against a secretory molecule akin to β -hCG, such as the design of IL-6 inhibitors utilizing *in silico* methodologies,¹³ the strategic importance of narrowing down potential drug candidates for subsequent *in vitro* validation cannot be ignored.

In light of the absence of identified chemical inhibitors against β -hCG to date, the present study leveraged *in silico* tools including ZDOCK,¹⁴ CastP,¹⁵ PrankWeb¹⁶ and the Schrödinger suite to facilitate the identification of prospective small molecules capable of inhibiting β -hCG. Validation of these findings was conducted *in vitro* utilizing the MTT assay, offering a novel avenue for the development of targeted therapies against BRCA1-defective cancers.

2 Results and discussion

2.1 Binding site residues of TGF β R-II on β -hCG

β -hCG interaction with TGF β R-II in promoting tumor progression *via* the Smad signalling pathway within BRCA1-defective cancers have been shown. The ZDOCK server was leveraged to discern the specific binding sites of TGF β R-II on β -hCG.

Fig. 1a illustrates the selection process that was used to scrutinize the top 10 models generated by the ZDOCK server. To note are the residues highlighted in red, symbolizing the exact binding sites of TGF β R-II on β -hCG, illuminating the critical molecular interfaces essential for their interaction. The boxes within Fig. 1a serve as indicators of the prevalence of these residues across the top 10 models, offering insights into the consistency and significance of these binding sites. The numerical annotations at the bottom of Fig. 1a indicate the specific residue numbers along the β -hCG chain to help map the interacting residues. This analysis not only enriches our understanding of the molecular underpinnings of tumor progression in BRCA1-defective cancers but also lays a robust groundwork to explore therapeutic strategies that target the interaction between β -hCG and TGF β R-II.

From Fig. 1b, it is evident that residues P-3, R-5, R-7, P-39, T-40, M-41, T-42, R-43, V-44, L-45, Q-46, L-52, P-53, V-55, R-60, Q-89 and C-90 exhibit a frequency of occurrence $\geq 50\%$ in the binding site residues of TGF β R-II on β -hCG within the top 10 complexes. Notably, residues P-39, T-40, M-41 and R-43 demonstrate the highest frequency of occurrence at 90%. These identified residues are anticipated to play a direct role in the binding interaction between β -hCG and TGF β R-II. Given the significance of these residues in the β -hCG-TGF β R-II interaction, thereby promoting tumor progression, exploring small molecules that target these specific residues could offer a promising therapeutic approach.

2.2 Binding site prediction using PrankWeb, CastP and SiteMap tool

The software tools PrankWeb, CastP and SiteMap in Schrödinger Maestro version 13.5 were used to pinpoint potential active sites, as shown in Fig. 1c. Notably, certain residues such as L-16 (predicted by PrankWeb and CastP), V-56 (predicted by SiteMap and PrankWeb), Y-59 (predicted by PrankWeb and CastP), A-83 (predicted by PrankWeb and CastP), T-98 (predicted by PrankWeb and SiteMap) and P-107, L-108 (predicted by CastP and SiteMap) exhibit overlapping predictions. Conversely, while some residues do not coincide, they are positioned adjacent to the overlapping residues, such as A-14 and T-15 (predicted by Schrödinger's SiteMap) and L-16 (predicted by PrankWeb). From these results, it can be concluded that the prediction of active site residues by different software shows similar results. The results from the SiteMap software were used for further analysis.

2.3 Virtual screening, molecular docking and MM-GBSA calculation

The suite of virtual screening and molecular docking tools within the Schrödinger software package, encompassing (HTVS) high throughput virtual screening, (SP) standard precision and (XP) extra precision, in conjunction with Desmond Prime for free energy calculations, facilitated the identification of the top five candidate molecules capable of potentially inhibiting β -hCG. Table 1 presents the top 5 molecules along with their docking scores and free energies (kcal mol^{-1}). Additionally, Table 2 showcases the molecular formula, molecular weight (M.W.) and structures of these small molecules, while ESI Table 2† delineates the SMILES format of the small molecules. These molecules are expected to bind to β -hCG, impeding its interaction with TGF β R-II. Several virtual libraries were used as mentioned in the Experimental section.

2.4 Bonding interactions of the identified inhibitors with β -hCG using molecular dynamics (MD) simulations

MD simulations were conducted over a duration of 100 ns, focusing on the interaction of five small molecules with β -hCG, including derivatives of compound 2,6,7-trihydroxy-9-(2-hydroxyphenyl)-3H-xanthen-3-one, specifically 2',7'-dichlorofluorescein and 2',7'-difluorofluorescein, all of which exhibited stable binding with β -hCG.






Fig. 1 (a) Top 10 models of the β -hCG sequence, depicting the binding site residues of TGF β R-II (highlighted in red) as predicted by the ZDOCK server. The numerical annotations at the bottom of the figure corresponds to the residue numbers on the β -hCG chain. Rectangular boxes within the figure indicate the prevalence of these residues across the top 10 models. (b) Displays the frequency of occurrence of the binding site residues in the top 10 models of β -hCG with TGF β R-II, as anticipated by the ZDOCK server. (c) A comparative analysis of the predicted active site residues of β -hCG generated by different software tools, namely, PrankWeb, SiteMap (Schrödinger), and CastP.

Among the small molecules identified, cefotetan demonstrated the most stable interaction with β -hCG. This compound established contacts with multiple residues of β -hCG, including






CYS-93, GLN-54, ARG-95, LEU-52, GLN-46, CYS-100, GLY-36, CYS-57 and CYS-38 (Fig. 2a). From the top ZDOCK 10 models in Fig. 1a, even if one of the models contained a binding site

Table 1 Top five small molecules along with their corresponding docking scores and free energies

Sl no.	Small molecule	Docking score	MMGBSA (kcal mol ⁻¹)
1	Cefotetan	-5.17	-45.44
2	F0922-590	-6.04	-60.77
3	F0385-0029	-5.61	-65.22
4	F6658-4634	-7.94	-42.34
5	2,6,7-Trihydroxy-9-(2-hydroxyphenyl)-3H-xanthen-3-one	-6.29	-47.01



Table 2 Assortment of potential small molecule inhibitors, their structures, docking scores, and free energies

Sl. no.	Name (molecular formula) and or (IUPAC name)	M.W. (a.u.)	Structure
1	Cefotetan (C ₁₇ H ₁₅ N ₇ O ₈ S ₄) (6 <i>R</i> ,7 <i>S</i>)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[[1-methyltetrazol-5-yl]sulfanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	573.607	
2	F0922-0590 (C ₃₅ H ₃₅ N ₃ O ₅) <i>N</i> -[2-(3,4-dimethoxyphenyl)ethyl]-4-({1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl} methyl)benzamide	577.686	
3	F0385-0029 (C ₂₈ H ₂₂ N ₄ O ₈ S ₄) 3-(4-{5-[(5 <i>E</i>)-3-{3-[(3-carboxyphenyl) carbamoyl]propyl}-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl}butanamido)benzoic acid	670.766	
4	F6658-4634 (C ₁₆ H ₂₀ N ₈ O ₂) 6-(4-{5,6-dimethyl-[1,2,4]triazolo[1,5- <i>a</i>]pyrimidin-7-yl}piperazin-1-yl)-3-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione	356.390	
5	2,6,7-Trihydroxy-9-(2-hydroxyphenyl)-3 <i>H</i> -xanthen-3-one (C ₁₉ H ₁₂ O ₆)	336.304	

residue of TGFβR-II on β-hCG, it would be considered, especially if it coincided with a residue maintaining hydrogen bonds (which are very important for drug design) with cefotetan. Therefore, residues GLN-54 (hydrogen bonding), LEU-52 (hydrogen bonding), GLN-46 (hydrogen bonding), CYS-100 (hydrogen bonding), GLY-36 (water bridges), CYS-57 (hydrogen bonding) and CYS-38 (water bridges) are mentioned (Fig. 1a and 2e). GLY-36 shows almost continuous contact throughout the set simulation with multiple points of contact in the contact timeline diagram of cefotetan (Fig. 2c), hence this residue is mentioned despite it forming only water bridges with cefotetan (Fig. 2e). At CYS-38, the RMSF shows a very stable value (within 1.6 Å) (Fig. 2d) and forms a point of contact indicated by a green vertical bar; therefore, this residue is being mentioned despite it forming only water bridges (Fig. 2e). ARG-95 was mentioned despite it not being a coinciding residue, as it contributes most significantly to the

hydrogen bond fraction (Fig. 2e), and CYS-93 contributes to a significant fraction of contact in the interactions diagram (Fig. 2a). The formation of a stable complex between cefotetan and β-hCG was evidenced by the RMSD plot (Fig. 2b), where the difference between the protein (shown in blue colour) and ligand (shown in red colour) is shown; RMSD remained consistently within 3 Å, indicating a stable interaction. The contacts timeline (Fig. 2c) visually represents the duration and intensity of specific residue-ligand contacts, with a darker shade of orange in Fig. 2c, denoting multiple contacts with the ligand. Throughout the 100 ns simulation period, cefotetan maintained continuous contacts with residues GLY-36, GLN-54, CYS-57, CYS-93 and ARG-95, with intermittent breaks. The RMSF plot (Fig. 2d) highlights the protein residues interacting with the ligand, depicted by green vertical bars. Lastly, the types of bonds formed between the residues and the ligand are illustrated in Fig. 2e, emphasizing the prevalence of hydrogen bonds.






Fig. 2 Robust binding of cefotetan with β -hCG. (a) Structural configuration with the interacting residues. (b) Protein–ligand RMSD plot. (c) Contact timeline. (d) RMSF visualization. (e) Delineation of the types of bonds established with the interacting residues of β -hCG.

Hydrogen bonds play a crucial role in drug design due to their strength and impact on drug specificity, metabolism and absorption. Notably, significant hydrogen bond interactions were observed at residues GLN-46, LEU-52, GLN-54, CYS-57, ARG-95 and CYS-100.

Compound F0922-0590, exhibited notable interactions at residues ASN-13, THR-32, CYS-34 and ALA-83 (Fig. 3a). The binding of this compound to β -hCG displayed remarkable stability, as evidenced by the RMSD plot (Fig. 3b). Throughout the simulation period, consistent contacts were observed,

particularly at residue ASN-13 and ALA-83, with intermittent breaks in between (Fig. 3c). The RMSF analysis (Fig. 3d) highlighted multiple points of contact, with a significant presence of hydrogen bonds at residues ASN-13, THR-32, CYS-34 and ALA-83 (Fig. 3e).

The interactions of compound F6658-4634, as illustrated in Fig. 4, demonstrate binding with the residues CYS-34, TYR-59, ALA-83 and ASP-99 of β -hCG (Fig. 4a). The binding between this compound and β -hCG exhibited stability, as indicated by the RMSD plot (Fig. 4b). Notably, a consistently stable contact was






Fig. 3 Robust binding of the compound F0922-0590 with β -hCG. (a) Structural configuration with the interacting residues. (b) Protein–ligand RMSD plot. (c) Contact timeline. (d) RMSF visualization. (e) Delineation of the types of bonds established with the contacting residues of β -hCG.

maintained throughout the simulation period at residue CYS-34 of β -hCG, while ALA-83 and ASN-99 residues displayed intermittent breaks but overall continuity (Fig. 4c). Analysis of the RMSF plot (Fig. 4d) revealed the establishment of several points of contact, with residue CYS-34 (Fig. 4e) exhibiting the most significant proportion of hydrogen bonding with the ligand.

Compound F0385-0029 exhibited multiple points of contact on β -hCG at residues TYR-59, THR-98, ARG-94, ASN-58, GLY-101 and CYS-57, as illustrated in Fig. 5a. The RMSD plot in Fig. 5b indicated a stable interaction, albeit showing a slight deviation around 80 ns, potentially attributed to the bulky side chains of the ligand.

The contacts timeline in Fig. 5c revealed continuous interactions at residues ASN-58 and TYR-59, with ARG-94 displaying recurrent contacts denoted by a darker shade of orange. The RMSF analysis (Fig. 5d) highlighted multiple points of contact. Notably, a significant proportion of hydrogen bonds were observed at residues CYS-57, ASN-58, ARG-94 and GLY-101, as depicted in Fig. 5e.

2,6,7-Trihydroxy-9-(2-hydroxyphenyl)-3*H*-xanthen-3-one exhibited multiple points of contact with β -hCG at residues TYR-59, ASN-58, CYS-34 and ILE-33 (Fig. 6a). The RMSD plot illustrated a stable interaction of the compound with β -hCG, as shown in Fig. 6b. The contacts timeline in Fig. 6c demonstrated






Fig. 4 Robust binding of the compound F6658-4634 with β -hCG. (a) Structural configuration with the contacting residues. (b) Protein–ligand RMSD plot. (c) Contact timeline. (d) RMSF visualization. (e) Delineation of the types of bonds formed with the contacting residues of β -hCG.

continuous contacts maintained at CYS-34. The RMSF analysis revealed several points of contact established, particularly around residue 100 of β -hCG (Fig. 6d). Notably, a significant proportion of hydrogen bonds are observed at residues CYS-34 and TYR-59, as depicted in Fig. 6e.

2',7'-Dichlorofluorescein, a derivative of compound 2,6,7-trihydroxy-9-(2-hydroxyphenyl)-3*H*-xanthen-3-one, exhibited contact at residue CYS-34 (Fig. 7a), a stable RMSD (Fig. 7b),

continuous contacts maintained at CYS-34 (Fig. 7c), several points of contact indicated by the RMSF plot (Fig. 7d) and a significant proportion of hydrogen bonds at CYS-34 (Fig. 7e).

2',7'-Difluorofluorescein, an additional derivative of compound 2,6,7-trihydroxy-9-(2-hydroxyphenyl)-3*H*-xanthen-3-one, demonstrated points of contact at CYS-34 (Fig. 8a), a consistent RMSD profile (Fig. 8b), nearly uninterrupted contacts at CYS-34 (Fig. 8c), multiple points of contact




Fig. 6 Robust binding of the compound 2,6,7-trihydroxy-9-(2-hydroxyphenyl)-3H-xanthen-3-one with β -hCG. (a) Structural configuration with the contacting residues. (b) Protein–ligand RMSD plot. (c) Contact timeline. (d) RMSF visualization. (e) Delineation of the types of bonds formed with the contacting residues of β -hCG.

2.6 β -hCG expression in cells

The media of various cell lines, such as MDA-MB-231, MDA-MB-231shBRCA1, MDA-MB-231 scrambled control, MDA-MB-231 BRCA1 sgRNA(1 + 2), MDA-MB-231 PCL-CTIG control and MDA-MB-468, were subjected to β -hCG ELISA (Abcam, ab178633), according to the manufacturer's instructions, alongside β -hCG

standards. β -hCG was found to be secreted in the highest amount of 4.44 ng ml^{-1} of media in MDA-MB-231 BRCA1 sgRNA(1 + 2) cell line, followed closely by MDA-MB-468, which showed 4 ng ml^{-1} of β -hCG secretion in media and MDA-MB-231 shBRCA1 at a concentration of 1.88 ng ml^{-1} . In the wild-type BRCA1 cell line, MDA-MB-231 and control for the knocked-down BRCA1 cell line






Fig. 7 Stable binding of 2',7'-dichlorofluorescein with β -hCG. (a) Structural configuration with the contacting residues. (b) Protein–ligand RMSD plot. (c) Contact timeline. (d) RMSF visualization. (e) Delineation of the types of bonds formed with the contacting residues of β -hCG.

MDA-MB-231 scrambled control, β -hCG was secreted at a concentration of 0.2 ng ml^{-1} . The control for CRISPR modified cell line, MDA-MB-231 PCL-CTIG exhibited 0.4 ng ml^{-1} secretion of β -hCG in media (Fig. 9a). These results indicate that β -hCG expression is associated with the BRCA1 status in various breast cancer cell lines *i.e.*, where the BRCA1 gene is defective, β -hCG expression was found to be present.

2.7 Cell proliferation assay

The cell lines employed in this assay include MDA-MB-231, MDA-MB-shBRCA1, MDA-MB-231 scrambled control, MDA-MB-231 BRCA1 sgRNA(1 + 2), MDA-MB-231 PCL-CTIG control and MDA-MB-468.






Fig. 8 Stable binding of 2',7'-difluorofluorescein with β -hCG. (a) Structural configuration with the contacting residues. (b) Protein–ligand RMSD plot. (c) Contact timeline. (d) RMSF visualization. (e) Delineation of the types of bonds formed with the contacting residues of β -hCG.

Cefotetan exhibited a notable decrease in viability in cell lines with defective BRCA1, as depicted in Fig. 9b. Specifically, MDA-MB-231 BRCA1 sgRNA 1 + 2, MDA-MB-231shBRCA1 and

MDA-MB-468 displayed reduced viability with escalating concentrations of cefotetan, while MDA-MB-231, MDA-MB-231 PCL-CTIG and MDA-MB-231 scrambled control exhibited no

Table 3 Coinciding interacting residues of TGF β R-II and inhibitors with β -hCG

Sl no.	Inhibitor	Coinciding residues of TGF β R-II and inhibitor binding site on β hCG (only hydrogen bonds considered except for F6658-463)
1	Cefotetan	R43, L45, Q46, L52, Q54, C57, R94, C100, G101
2	F0922-0590	A83, K104, H106
3	F6658-4634	Y59 (hydrophobic), A83 (hydrophobic and water bridges), D99 (water bridges), D105 (water bridges)
4	F0385-0029	R6, G36, T40, R43, Q46, Q54, V55, C57, R94, T98, G101, G102, P103, H106
5	2,6,7-Trihydroxy-9-(2-hydroxyphenyl)-3H-xanthen-3-one	Y59
6	2,7-Dichlorofluorescein	LEU-45, GLN-46, CYS-57, TYR-59, GLY-101
7	2,7-Difluorofluorescein	CYS-57, TYR-59, THR-98, ASN-99, CYS-100

significant viability alteration with increasing cefotetan concentrations.

2',7'-Dichlorofluorescein diacetate was analyzed in the study, as 2',7'-dichlorofluorescein alone lacks cell permeability. However, the diacetate salt can penetrate cells and undergo cleavage by intracellular esterases to generate 2',7'-dichlorofluorescein. To maintain cell viability, the concentrations of DCFDA in the MTT assay were restricted to 10 μ M, considering that higher DCFDA concentrations (>10 μ M DCFDA) have been reported to compromise cell viability.²⁴ Fig. 9c depicts a reduction in viability noted in BRCA1-defective cell lines, including MDA-MB-231 shBRCA1 and MDA-MB-231 BRCA1 sgRNA 1 + 2, as compared to their corresponding controls, namely MDA-MB-231 scrambled control and MDA-MB-231 PCL-CTIG control, respectively. These results were comparable to the control BRCA1-defective cell line, MDA-MB-468.

The MTT assay was also performed in various cell lines using the β -hCG monoclonal antibody (sc-271062, Santa Cruz). As can be seen in Fig. 9d, increasing concentrations of the antibody exhibited decreased viability in cell lines having the BRCA1-defective gene (namely MDA-MB-231 shBRCA1, MDA-MB-231 BRCA1 sgRNA 1 + 2 and MDA-MB-468), which also express β -hCG. However, their BRCA1 wild-type counterparts, namely the MDA-MB-231, MDA-MB-231 scrambled control and MDA-MB-231 PCL-CTIG control, did not show any alteration in viability.

Compounds F0922-0590, F6658-4634, F0385-0029, along with 2,7-difluoro-fluorescein, underwent cell viability testing exclusively in MDA-MB-231 BRCA1 sgRNA 1 + 2, its control, MDA-MB-231 PCL-CTIG and the parent cell line MDA-MB-231. The results revealed diminished viability for all four compounds, specifically in the MDA-MB-231 BRCA1 sgRNA 1 + 2 cell line, characterized by induced hypermethylation in the BRCA1 promoter leading to reduced BRCA1 expression, as depicted in Fig. 10a–d. Despite employing concentrations as high as 100 μ M for each compound, viability reduction below 50% was not achieved.

All experiments were conducted using GraphPad Prism, where 'ns' denotes non-significant and **** indicates $p < 0.0001$. The β -hCG monoclonal antibody showed selective inhibition in BRCA1-defective cell lines.

2.8 Binding interaction

MST revealed that out of the six inhibitors obtained from *in silico* studies, the hCG molecule binds to cefotetan and F0922-

0590 alone. Binding affinity determination revealed that hCG binds cefotetan with a $K_D = 4.6 \pm 3 \mu$ M. The affinity of compound F0922-0590 was found to be $K_D = 0.388 \pm 0.009$ mM. ITC showed cefotetan to have a $K_D = 5.43 \pm 2.99 \mu$ M (very close to that determined by MST). F0922-0590 did not show any binding with ITC (Fig. 11). These results confirm the fact that cefotetan binds β -hCG and causes a selective cytotoxic effect in β -hCG-expressing cells.

2.9 Discussion

To identify the chemical inhibitors targeting β -hCG, which interacts with TGF β R-II and initiates tumor progression *via* the Smad signaling pathway in BRCA1-defective cancers, the interacting residues of β -hCG with TGF β R-II were identified from the top 10 models generated by ZDOCK. Subsequently, the active/druggable sites of β -hCG were delineated and compared utilizing various software tools. A comprehensive virtual screening of chemical molecules from multiple virtual libraries, totalling 127 846 molecules, was conducted against the identified active sites. Subsequently, docking simulations of these molecules were executed, followed by free energy calculations. The most promising complexes resulting from these analyses underwent a rigorous 100 ns simulation. This meticulous process culminated in the identification of the top six molecules.

These selected molecules then underwent cell viability assessments, such as MTT assays, across several BRCA1-defective and BRCA1 wild-type cell lines. Notably, among the BRCA1-defective cell lines evaluated, a novel cell line developed in our laboratory was included. This unique cell line was derived from the modification of the wild-type BRCA1 cell line MDA-MB-231, inducing hypermethylation at the BRCA1 promoter using modified CRISPR technology. Additionally, another BRCA1-defective cell line was established through stable knock-down of the BRCA1 gene.

Specifically, cefotetan was found to bind to residues R43, L45, Q46, L52, Q54, C57, R94, C100 and G101, which align with the predicted TGF β R-II binding site on β -hCG, as anticipated by ZDOCK. The outcomes of all MTT assays conducted consistently demonstrated that cefotetan exhibited the most notable reduction in cell viability in BRCA1-defective cell lines at a concentration as low as 30 μ M. Table 4 represents the IC_{50} value of cefotetan and β -hCG monoclonal antibody as predicted by GraphPad Prism v10.2.2 using the Hill slope equation.






Fig. 9 (a) Secretion of β -hCG in the supernatant of various cell lines. (b) Cytotoxic impact of cefotetan on diverse cell lines. (c) Cytotoxic impact of 2',7'-dichlorofluorescein diacetate (DCFDA) on different cell lines. (d) Cytotoxic effect of the β -hCG monoclonal antibody on different cell lines.

Although cefotetan showed a K_D in the micromolar range, it is still significant, as we have used whole hCG instead of β -hCG. Most of the active site residues used for virtual screening, molecular docking and dynamic simulation fall in the region where β -hCG interlocks with α -hCG. There is a chance that antiproliferative activity of cefotetan may not be by binding to hCG but the fact that the reduction in cell viability was selectively seen particularly in the β -hCG-expressing cells when compared to cells that do not express β -hCG (Fig. 9a and b) and

are comparable to the effects of the β -hCG monoclonal antibody (Fig. 9d). Therefore, there is a high chance that the selective cytotoxic effects of cefotetan could be due to its interaction with β -hCG. The MST/ITC techniques revealed that cefotetan would bind to hCG; however, to identify which specific residues on β -hCG would bind cefotetan, techniques like X-ray crystallography, NMR or SPR could be used.

Cefotetan, an FDA-approved bactericidal agent classified within the cephamycin subclass of second-generation




Fig. 10 (a) Cytotoxic impact of the compound F0922-0590 on diverse cell lines. (b) Cytotoxic influence of the compound F6658-4634 on a range of cell lines. (c) Cytotoxic impact of the compound F0385-0029 on different cell lines. (d) Cytotoxic effect of 2,7-difluorofluorescein on different cell lines.

cephalosporins,²⁵ exerts its mechanism of action by impeding cell wall synthesis through disruption of peptidoglycan cross-linking mediated by penicillin-binding proteins.²⁶ Additionally, cefotetan triggers the activation of bacterial autolysins, thereby facilitating cell lysis²⁷ Notably, cefotetan monotherapy has demonstrated reduced rates of both inpatient and outpatient antibiotic utilization in comparison to non-cefotetan prophylaxis for Gustilo–Anderson type III open long bone fractures.²⁸ The utilization of cefotetan as a standalone prophylactic measure may offer enhanced antibiotic stewardship for Gustilo–Anderson type III open long bone fractures when juxtaposed with traditional antibiotic prophylaxis regimens.²⁹ Despite its established role as a bactericidal agent, there is a paucity of literature regarding the potential anti-cancer properties of cefotetan. This study is the first of its kind in exploring the cytotoxic effects of cefotetan in BRCA1-defective breast cancer cell lines compared to wild-type BRCA1 breast cancer cell lines. This study has been filed for US Provisional Patent. (Srinivas,Priya and Ittycheria,Shreya.2025. Repurposing FDA-approved Drug Cefotetan, as a Novel Anticancer Avenue Through Inhibition of β -hCG and its mechanism for the process of inhibition thereof. US Provisional Application Serial No. 63/799,963, filed May 5, 2025).

While PARP inhibitors have shown promise as a therapeutic avenue for BRCA1-defective cancers, a substantial proportion of patients (40-70%) have developed resistance over time.³⁰ Given the existing FDA approval status of cefotetan as a bactericidal agent, the potential repurposing of this drug for the treatment of BRCA1-defective cancers, contingent upon efficacy in animal studies, emerges as a compelling prospect.

Numerous vaccines targeting β -hCG and α -hCG have been developed, including a conjugated toxoid,³¹ a recombinant chimeric antibody cPiPP, a curcumin-conjugated variant selectively toxic to β -hCG expressing cells,³² and Ovidrel, a recombinant α -hCG vaccine that has exhibited an impact on the RNA expression of BRCA1-defective breast cancer tissues.³³ However, the production of antibodies is costly and may elicit adverse reactions in humans, particularly in pregnant women.³⁴ In contrast, chemical inhibitors offer a distinct advantage by circumventing the occurrence of adverse reactions.

3 Experimental

3.1 *In silico* analysis

The computational analyses encompassing protein preparation, virtual screening, molecular docking, MM-GBSA






Fig. 11 (a) MST shows binding of six compounds to the hCG molecule. Only cefotetan and the compound F9922-0590 are seen to bind hCG. (b) Binding affinity of cefotetan to hCG with a $K_D = 4.6 \pm 3 \mu\text{M}$ (c) and F9922-0590 with a $K_D = 0.388 \pm 0.009 \text{ mM}$. (d) ITC shows binding of cefotetan to hCG with $K_D = 5.43 \pm 32.99 \mu\text{M}$. (e) No binding between F9922-0590 and hCG.



Table 4 IC₅₀ values of cefotetan and β-hCG monoclonal antibody as identified by the MTT assay and predicted by GraphPad Prism 10.2.2

Sl no.	Drug	IC ₅₀
1	Cefotetan	32.56 μM
2	β-hCG monoclonal antibody	3.17 ng

calculation and molecular dynamic simulations were executed utilizing Maestro Schrödinger v13.5. These analyses were conducted on a Dell computer, equipped with a Windows 11 operating system, an Intel Core i7 processor and 16 GB RAM, ensuring optimal performance and reliability throughout the investigative process.

3.1.1 Protein structure retrieval. The protein structures of β-hCG (PDB ID: 1HCN, with alpha chain deleted) and TGFβR-II (PDB ID: 1PLO; specifically utilizing the initial model) were acquired from the Protein Data Bank (PDB) website located at <https://www.rcsb.org/>.

3.1.2 Docking β-hCG with TGFβR-II. Docking procedures for the acquired PDB structures of β-hCG and TGFβR-II were done using the ZDOCK server. The respective PDB IDs of β-hCG and TGFβR-II were fed into the designated fields on the ZDOCK server interface. Subsequently, the top 10 anticipated models were selected to elucidate the interacting residues between β-hCG and TGFβR-II. Visualization of the models was conducted using Pymol, which facilitated the identification of the interacting residues between β-hCG and TGFβR-II. See ESI 1† for the sequence details.

3.1.3 Active site/binding site identification. This was done using CastP, PrankWeb and Schrödinger's SiteMap. Through a systematic approach, the active sites were identified and an in-depth comparison was performed to evaluate the consistency and discrepancies among the predicted binding site residues generated by these software tools. PrankWeb, CastP and SiteMap¹⁸ tool of Schrödinger maestro represent software tools employed for the identification of active sites within diverse molecules. Each of these identified sites is then evaluated and assigned scores based on the constituent residues. The scores of the identified sites, along with the pocket score and amino acid count, serve as indicators of the suitability of a site for drug targeting, with higher scores indicating greater potential for targeting.

3.1.4 Protein preparation. The crystallographic structure of β-hCG was obtained from the Protein Data Bank (PDB), capturing the complete hCG structure at a resolution of 2.6 Å, as determined by X-ray crystallography. It is to be noted that the alpha chain was intentionally omitted from the acquired structure, as β-hCG is the subunit that is expressed in BRCA1-defective cancers, as we had reported earlier and not α-hCG.^{5–9} Prior to molecular docking, the advanced Protein Preparation Wizard of the Schrödinger Maestro version 13.5 software suite was applied. This preparatory phase is crucial for maintaining the structural integrity and reliability of the protein and prepares it for subsequent molecular docking and dynamic simulations. It involves the addition of absent hydrogen atoms,

the removal of water molecules co-crystallized within the structure, the assignment of partial charges and the execution of a restrained minimization process. This process targets both hydrogen and heavy atoms and is conducted with the OPLS4 force field.¹⁹

3.1.5 Binding site selection and receptor grid generation.

Scores are assigned to the various active sites identified by Schrödinger's SiteMap. The active site with the highest score, as predicted by Schrödinger's SiteMap, was used for grid generation. The corresponding grid file was generated using the Receptor Grid Generation panel in the Glide module of Schrödinger Maestro version 13.5 with default parameters and was further used to perform the molecular docking protocol.²⁰

3.1.6 Ligand preparation. A total of 127 846 small molecules sourced from diverse small molecule screening libraries, including ZINC (in which the “anticancer” filter was applied), NCI, Chembridge, ChemDB and LifeChemicals (in which the “anticancer compounds” filter was applied), were acquired in SDF format, details of which are given in ESI Table 1.† Ligand preparation was conducted utilizing the LigPrep module within Schrödinger Maestro version 13.5.²¹ This process involved the expansion of tautomeric and ionization states of the compounds, generation of ring conformations and production of stereoisomers to establish the ligand library (see ESI 2†).

3.1.7 Receptor-based high-throughput virtual screening and docking. To screen the prepared ligand library against the designated binding pockets, the Glide Module within Schrödinger was utilized, implementing a sequence of three distinct levels of virtual screening and rigid receptor docking. These stages encompass high-throughput virtual screening (HTVS), standard precision (SP) and extra precision (XP) modules. Each successive stage entails increased stringency, with only compounds exhibiting top docking scores progressing to the subsequent stage; specifically, compounds with docking scores ≤ −5 were specifically chosen for further analysis.

3.1.8 Free binding energy calculation using MM-GBSA. The docking outcomes revealed that the chosen ligands engage with the active site of β-hCG through the receptor grid. However, whether this binding interaction would elicit a biological response hinges primarily on the free binding energies of the protein–ligand complex. The binding affinities for the top-ranking compounds were evaluated utilizing the Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) approach within the Prime module²² of Schrödinger Maestro version 13.5. This involved rescoring the docked poses of the ligand molecules to derive the binding free energies and assess the relative binding strengths. The MM-GBSA calculations were performed with default parameters, employing the VSGB 2.1 implicit solvation model and OPLS4 force field within the Prime framework. Each library was screened one after the other and not all together, from the Ligprep stage onwards till MD simulation and only after completing each library was the next one started from Ligprep. The details are indicated in ESI Table 3.†

3.1.9 Molecular dynamics (MD) simulation. To assess the binding stability of the identified candidate compounds cefotetan, F0922-0590, F6658-4634, F0385-0029 and 2,6,7-trihydroxy-9-(2-hydroxyphenyl)-3H-xanthen-3-one within the



designated protein active site cavity, an in-depth analysis of the complex structure was conducted through 100 ns (nanoseconds) (MD) simulations. Given the challenges in synthesizing compound 2,6,7-trihydroxy-9-(2-hydroxyphenyl)-3H-xanthen-3-one, molecular dynamic simulations were instead performed on its derivatives, specifically 2',7'-dichlorofluorescein and 2',7'-difluorofluorescein. The MD simulations were executed using the Desmond module in Schrödinger Maestro version 13.5 (ref. 23) (ESI 2†).

Prior to initiating the 100 ns simulations, a simulation box was constructed for the protein–ligand complexes of interest using the System Builder tool within Desmond. The system was solvated using the TIP3P water model, with an orthorhombic periodic boundary box shape set at a distance of 10 Å on both sides to ensure a consistent volume. To maintain system neutrality, appropriate ions such as Na⁺ and Cl[−] were introduced randomly into the solvated system at a salt concentration of 0.15 M. Subsequently, the system underwent a minimization and relaxation process following the default protocol integrated within the Desmond module, employing the OPLS4 force field parameters post the construction of the solvated system containing the protein–ligand complex.

Visualization aids, including plots and figures, were generated using the Simulation Interaction Diagram tool within Maestro. The assessment of the stability of the complex structure was conducted based on various parameters derived from the trajectory output, encompassing root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), protein–ligand contacts (P–L contact) and hydrogen bond interactions.

3.1.10 Root mean square deviation (RMSD) analysis. The RMSD in MD simulations serves as a pivotal metric quantifying the average displacement distance of a designated atom over a specified duration with regard to a reference time point. Initially, the RMSD computation entails the assessment of the positional variances of essential β-hCG protein structural components, such as the Cα backbone, sidechain and heavy atoms. Subsequently, the RMSD determination extends to the alignment and calculation of the RMSD values for the protein-fitted ligand atoms across all time frames in correlation to the reference time point (in this instance, 100 ns).

3.1.11 Root mean square fluctuation (RMSF) analysis. RMSF is useful for characterizing local changes along the protein chain. Interpreting the RMSF plot, peaks serve as indicators of regions within the protein structure, exhibiting the highest fluctuations during the simulation. Typically, the terminal regions (N- and C-terminal) demonstrate more pronounced fluctuations compared to other protein segments. Structurally defined elements such as alpha helices and beta strands tend to exhibit greater rigidity in contrast to unstructured protein regions, resulting in comparatively lower fluctuation levels, particularly within the loop regions. Notably, protein residues engaging in interactions with the ligand are distinctly highlighted through the incorporation of green-coloured vertical bars. Furthermore, a graphical representation delineating the temporal evolution of interactions and contacts, encompassing hydrogen bonds, hydrophobic interactions, ionic interactions and water bridges, is presented. The

upper panel of this representation illustrates the cumulative count of specific contacts established by the protein with the ligand throughout the trajectory. Conversely, the lower panel provides insights into the residues engaging in interactions with the ligand across individual frames within the trajectory. Noteworthy is the differentiation in shading intensity, with darker shades of orange denoting residues forming multiple specific contacts with the ligand, as indicated by the scale positioned to the right of the plot.

3.2 Experimental procedure

3.2.1 Development of a novel cell line with induced BRCA1 promoter hypermethylation using modified CRISPR technology. A novel cell line was developed in our lab wherein a hypermethylated BRCA1 promoter was generated using modified CRISPR-Cas9 technology, using the MDA-MB-231 cell line that has wild-type BRCA1. Briefly, the CpG island target sequences were procured from NCBI (GenBank ID U37574), and then these sequences were entered into the MIT sgRNA design software (<https://crispr.mit.edu/>). sgRNAs were subsequently selected based on relative location to other sgRNAs. The oligonucleotides of sgRNA and shRNA were fused, which was then cloned into the pLVTHM vector. The cell line HEK 293T was used to generate lentiviral particles using psPax2 and pMD2.G, which are lentiviral plasmids. This was then transduced to the cell line, MDA-MB-231. The target cells were co-transduced with lentiviral particles and pCL-CTIG of Tet-O-Cas9-D3A for the generation of stable methylated cells under the control of a Tet-Off promoter. Lentiviral particles containing either sgRNA1 or sgRNA2 or both were infected into the cells and treatment with 1 μg ml^{−1} of doxycycline was given for half a day to arrest the eGFP signal emitted from PCL-CTIG. Flow cytometry was finally used to sort the eGFP-positive population, which represents sgRNA-positive cells and this establishes the stably transduced cell line. The induction of promoter hypermethylation was validated by methylation-specific qPCR, western blot and real-time PCR.¹⁷

3.2.2 ELISA for β-hCG detection. Media from various cell lines, MDA-MB-231, MDA-MB-468, MDA-MB-231shBRCA1 (with BRCA1 knockdown), MDA-MB-231 scrambled control (control cell for BRCA1 knockdown), MDA-MB-231 sgRNA(1 + 2) [cell line induced with BRCA1 promoter hypermethylation using modified CRISPR technology] and MDA-MB-231 PCL-CTIG [control for MDA-MB-231 sgRNA(1 + 2)] was subjected to β-hCG ELISA (Abcam, ab178633), according to the manufacturer's instructions, alongside the β-hCG standards.

3.2.3 Cytotoxic assay – MTT assay. The cytotoxic effect of the identified compounds on both BRCA1-defective (cell lines MDA-MB-468, MDA-MB-231shBRCA1 and MDA-MB-231 sgRNA(1 + 2)) and BRCA1 wild type (cell lines – MDA-MB-231, MDA-MB-231 scrambled control and MDA-MB-231 PCL-CTIG) was investigated using the MTT assay. Briefly, cells were treated with varying concentrations of F6658-4634, cefotetan, F0922-0590, F0385-0029, 2',7'-dichlorofluorescein (DCF) and 2',7'-difluorofluorescein (DFF), mixed in DMEM containing 2.5% FBS, replacing the existing media. The compounds were



dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA), with sub-stocks prepared in 2.5% FBS containing DMEM. The β -hCG monoclonal antibody at varying concentrations served as the positive control. Following a 48 hour incubation period with the drug compounds, cells were treated with MTT at a final concentration of 0.125 mg ml⁻¹ and incubated at 37 °C for 2 hours. Subsequently, a lysis buffer comprising dimethylformamide (ThermoScientific, Cat No. 043465.AP), 20% sodium dodecyl sulphate (SDS, Invitrogen, cat no. 15525-017) and distilled water were added. The absorbance at 595 nm was measured using a Bio-rad iMark™ microplate reader. Two-way ANOVA test was done using GraphPad Prism version 10.

3.2.4 Microscale thermophoresis (MST). MST was employed for validating the binding of the identified compounds using the *in silico* methods. The hCG molecule was initially labelled using the Protein Labeling Kit RED-NHS 2nd Generation (Cat# MO-L011) according to the manufacturer protocols. The MicroScale Thermophoresis Monolith NT 115 system NanoTemper Technology, Germany, available at the National Institute of Animal Biotechnology, Hyderabad (under the supervision of Dr Pankaj Suman), was employed for determining the binding as well as the affinity of binding of the identified compounds. For checking affinity, 10 μ l of the labelled protein was added to 16 tubes. To the first tube, 10 μ l of the ligand (50 μ M) was added, mixed well and 10 μ l was taken from the first tube and added to the second. This process was repeated till the last tube. This was then loaded onto 16 standard treated capillaries and run on the MST machine.

The dilution concentrations were entered into a dedicated MO affinity analysis software to determine K_D .

3.2.5 Isothermal calorimetry (ITC). ITC was done using MICROCAL PEA1-ITC, Malvern at the Centre for Cellular and Molecular Biology (CCMB), Hyderabad. Degassing was done on MicroCal ThermoVac, GE followed by injection of protein and ligands (cefotetan and compound F0922-0590) in separate compartments.

For all the *in vitro* experiments, at least 3 biological replicates were done to calculate the standard deviation and the *p* values.

4 Conclusion

In this investigation, six potential small molecule inhibitors, out of 127 846 small molecules, targeting β -hCG at sites coinciding with those of TGF β R-II's binding site on β -hCG, was identified through the employment of diverse *in silico* methodologies. Particularly, cefotetan exhibited the most promising outcomes in BRCA1-defective breast cancer cell lines compared to all other compounds. The FDA-approved antibacterial agent, cefotetan, though it showed a weak interaction with hCG in MST and ITC, is found to be promising as a cytotoxic agent against β hCG positive breast cancer cells compared to the β -hCG monoclonal antibody. The binding experiments show a possibility of cefotetan binding to β -hCG and could be potentially causing the inhibition in BRCA1-defective cell lines through binding β -hCG and preventing it from interacting with TGF β R-II. *Binding experiments show that cefotetan may interact*

with β -hCG, preventing it from activating the TGF β R-II signalling, which induces cytotoxicity in BRCA1-defective cancer cell lines. Future studies will include experiments such as affinity chromatography of the cell's contents coupled with mass spectra techniques to prove the interaction between cefotetan and β -hCG. Although the compounds DCF, DFF, F0922-0590, F6658-4634, and F0385-0029 demonstrated noteworthy efficacy in BRCA1-defective breast cancer cell lines, their individual impact did not reach a level of significance warranting consideration as standalone therapeutic modalities for BRCA1-defective breast cancers. Prior to advancing to clinical trials, it is imperative to conduct further investigations utilizing animal models to ascertain the safety and efficacy profiles of these compounds comprehensively.

Data availability

The data supporting this article have been included as part of the ESI.†

Author contributions

Shreya Sara Ittycheria: investigation, methodology, software, validation, formal analysis, data curation, writing – original draft, and visualization; Krishnankutty Chandrika Sivakumar: software, and writing – review & editing; Nagarjun Narayanan, Pankaj Suman: methodology, writing – review & editing; Dipyaman Patra: methodology; Bhavana Ramachandran, R. L. Neetha., Arathy V. Warriar M. A. Aiswarya and S. Kaviya: writing – review & editing; Priya Srinivas: conceptualization, investigation, resources, writing – review & editing, supervision, project administration, and funding acquisition.

Conflicts of interest

There is no interest to declare.

Acknowledgements

The research obtained funding from CSIR [Sanction Order No. 37WS (0059)/2023-24/EMR-II/ASPIRE], ICMR [Sanction Order No. EMDR/SGI1312023-2686] and RGCB Intramural. The authors wish to thank Dr Shijulal-Nelson Sathi and the Bioinformatics team at Rajiv Gandhi Centre for Biotechnology, Akkulam – 695011, for providing the necessary support for conducting the *in silico* study. The authors wish to express their gratitude to Didier Trono for the vector plasmid, pLVTHM (Addgene plasmid #12247), lentiviral plasmids psPax2 and pMD2.G (Addgene plasmid #12260 & Addgene plasmid #12259), vector, pLVTHM (Addgene plasmid #12247), lentiviral particles of TetO-dCas9-D3A (Addgene plasmid # 78254) and pCL-CTIG (Addgene plasmid # 149021), which are required for the development of BRCA1 promoter hyper-methylation induced cell line. The authors also wish to thank Ratheeshkumar Thankappan for helping with CRISPR cloning.



References

- 1 International Agency for Research on Cancer (IARC), *Cancer statistics report worldwide*, 2022, <https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer&sexes=2>, accessed 4 July, 2024.
- 2 International Agency for Research on Cancer (IARC), *Cancer statistics report worldwide*, 2022, <https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer&sexes=2&types=1>, accessed 4 July, 2024.
- 3 X. Zhu, L. Shan, F. Wang, J. Wang, F. Wang, G. Shen, X. Liu, B. Wang, Y. Yuan, J. Ying and H. Yang, Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer, *Breast Cancer Res. Treat.*, 2015, **150**, 4, DOI: [10.1007/s10549-015-3338-y](https://doi.org/10.1007/s10549-015-3338-y).
- 4 R. K. Iles, Ectopic hCG β expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis, *Mol. Cell. Endocrinol.*, 2007, **260**, 264–270, DOI: [10.1016/j.mce.2006.02.019](https://doi.org/10.1016/j.mce.2006.02.019).
- 5 S. K. Sengodan, R. Nadhan, R. S. Nair, S. K. Hemalatha, V. Somasundaram, R. R. Sushama, A. Rajan, N. R. Latha, G. R. Varghese, J. M. Kumar and A. Chil, BRCA1 regulation on β -hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer, *Oncogenesis*, 2017, **6**(9), e376, DOI: [10.1038/onsis.2017.75](https://doi.org/10.1038/onsis.2017.75).
- 6 S. K. Sengodan, A. Rajan, S. K. Hemalatha, R. Nadhan, A. Jaleel and P. Srinivas, Proteomic profiling of β -hCG-induced spheres in BRCA1 defective triple negative breast cancer cells, *J. Proteome Res.*, 2018, **17**(1), 276–289, DOI: [10.1021/acs.jproteome.7b00562](https://doi.org/10.1021/acs.jproteome.7b00562).
- 7 S. K. Sengodan, S. K. Hemalatha, R. Nadhan, T. Somanathan, A. P. Mathew, A. Chil, J. Kocczynski, R. S. Nair, J. M. Kumar and P. Srinivas, β -hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue, *Carcinogenesis*, 2019, **40**(11), 1415–1426, DOI: [10.1093/carcin/bgz070](https://doi.org/10.1093/carcin/bgz070).
- 8 R. Nadhan, J. V. Vaman, S. K. Sengodan, S. K. Hemalatha, N. Chellappan, S. Sadasivan, A. Pasuthottiyil Varkey, S. Yesodharan, K. Raji Sathyanpillai, A. K. Bhuvaneshwari Venugopal and S. Prameelakumari Sreenivasan, BRCA1 promoter hypermethylation in human placenta: a hidden link with β -hCG expression, *Carcinogenesis*, 2020, **41**(5), 611–624, DOI: [10.1093/carcin/bgz117](https://doi.org/10.1093/carcin/bgz117).
- 9 G. R. Varghese, D. Patra, V. S. Jaikumar, A. Rajan, N. R. Latha and P. Srinivas, β hCG mediates immune suppression through upregulation of CD11b⁺ Gr1⁺ myeloid derived suppressor cells, CD206⁺ M2 macrophages, and CD4⁺ FOXP3⁺ regulatory T-cells in BRCA1 deficient breast cancers, *Immunology*, 2023, **170**(2), 270–285, DOI: [10.1111/imm.13673](https://doi.org/10.1111/imm.13673).
- 10 A. Mohammed, T. Ahmed, R. R. Bhat, E. Mallik and A. Arulprakasam, Association of serum beta hCG levels in women with palpable malignant breast lesions, *Sci. Rep.*, 2023, **13**(1), 13208.
- 11 M. Ascoli, P. Narayan, J. L. Strauss and R. L. Barbieri, The gonadotropin hormones and their receptors, *Yen and Jaffe's Reproductive Endocrinology*, Saunders/Elsevier, Philadelphia, PA, 7th edn, 2013, pp. 27–44.
- 12 J. Massagué, TGF β signalling in context, *Nat. Rev. Mol. Cell Biol.*, 2012, **13**(10), 616–630, DOI: [10.1038/nrm3434](https://doi.org/10.1038/nrm3434).
- 13 A. K. Swaroop, P. K. Namboori, M. Esakkimuthukumar, T. K. Praveen, P. Nagarjuna, S. K. Patnaik and J. Selvaraj, Leveraging decagonal in-silico strategies for uncovering IL-6 inhibitors with precision, *Comput. Biol. Med.*, 2023, **163**, 107231, DOI: [10.1016/j.combiomed.2023.107231](https://doi.org/10.1016/j.combiomed.2023.107231).
- 14 B. G. Pierce, K. Wiehe, H. Hwang, B. H. Kim, T. Vreven and Z. Weng, ZDOCK server: interactive docking prediction of protein–protein complexes and symmetric multimers, *Bioinformatics*, 2014, **30**(12), 1771–1773, DOI: [10.1093/bioinformatics/btu097](https://doi.org/10.1093/bioinformatics/btu097).
- 15 W. Tian, C. Chen, X. Lei, J. Zhao and J. Liang, CASTp 3.0: computed atlas of surface topography of proteins, *Nucleic Acids Res.*, 2018, **46**(W1), W363–W367, DOI: [10.1093/nar/gky473](https://doi.org/10.1093/nar/gky473).
- 16 L. Jendele, R. Krivak, P. Skoda, M. Novotny and D. Hoksza, PrankWeb: a web server for ligand binding site prediction and visualization, *Nucleic Acids Res.*, 2019, **47**(W1), W345–W349, DOI: [10.1093/nar/gkz424](https://doi.org/10.1093/nar/gkz424).
- 17 D. Patra, G. R. Varghese, V. S. Jaikumar, A. Rajan, N. Krishnan, K. Kuppaswamy, R. Thankappan and P. Srinivas, BRCA1 Hypermethylation In Sporadic Breast Cancers: Discovering A Novel Pathway To Tumorigenesis Via Coordinate NBR2 Deregulation And TNBC Transformation, *BioRxiv*, 2022, p. 2022-04.
- 18 *SiteMap: Schrödinger Release 2024-2*, Schrödinger, LLC, New York, NY, 2024.
- 19 C. Lu, C. Wu, D. Ghoreishi, W. Chen, L. Wang, W. Damm, G. A. Ross, M. K. Dahlgren, E. Russell, C. D. Von Bargen and R. Abel, OPLS4: Improving force field accuracy on challenging regimes of chemical space, *J. Chem. Theory Comput.*, 2021, **17**(7), 4291–4300, DOI: [10.1021/acs.jctc.1c00302](https://doi.org/10.1021/acs.jctc.1c00302).
- 20 *Glide: Schrödinger Release 2024-2*, Schrödinger, LLC, New York, NY, 2024.
- 21 *Schrödinger Release 2024-2: LigPrep*, Schrödinger, LLC, New York, NY, 2024.
- 22 S. Sirin, R. Kumar, C. Martinez, M. J. Karmilowicz, P. Ghosh, Y. A. Abramov, V. Martin and W. Sherman, *J. Chem. Inf. Model.*, 2014, **54**, 2334–2346, DOI: [10.1021/ci5002185](https://doi.org/10.1021/ci5002185).
- 23 *Desmond: Schrödinger Release 2024-2: Desmond Molecular Dynamics System*, D. E. Shaw Research, New York, NY, 2024.
- 24 D. Figureueroa, M. Asaduzzaman and F. Young, Real time monitoring and quantification of reactive oxygen species in breast cancer cell line MCF-7 by 2', 7'-dichlorofluorescein diacetate (DCFDA) assay, *J. Pharmacol. Toxicol. Methods*, 2018, **94**, 26–33, DOI: [10.1016/j.vascn.2018.03.007](https://doi.org/10.1016/j.vascn.2018.03.007).
- 25 A. Ward and D. M. Richards, Cefotetan: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use, *Drugs*, 1985, **30**, 382–426.
- 26 T. Bui and C. V. Preuss, Cephalosporins, in *StatPearls [Internet]*, StatPearls Publishing, 2024.



- 27 P. Periti and T. Mazzei, Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review, *J. Chemother.*, 1998, **10**(6), 427–448, DOI: [10.1179/joc.1998.10.6.427](https://doi.org/10.1179/joc.1998.10.6.427).
- 28 G. G. Via and M. J. Prayson, Monotherapeutic cefotetan surgical prophylaxis: Current evidence and practice for orthopaedic surgeons, *Journal of Orthopaedic Reports*, 2023, 100215, DOI: [10.1016/j.jorep.2023.100215](https://doi.org/10.1016/j.jorep.2023.100215).
- 29 G. G. Via, D. A. Brueggeman, V. A. Murray, A. W. Froehle, S. D. Burdette and M. J. Prayson, Use of single agent Cefotetan for Gustilo-Anderson type III open fracture prophylaxis, *Injury*, 2023, **54**(8), 110914, DOI: [10.1016/j.injury.2023.110914](https://doi.org/10.1016/j.injury.2023.110914).
- 30 D. Kim and H. J. Nam, PARP inhibitors: clinical limitations and recent attempts to overcome them, *Int. J. Mol. Sci.*, 2022, **23**(15), 8412, DOI: [10.3390/ijms23158412](https://doi.org/10.3390/ijms23158412).
- 31 G. P. Talwar, H. K. Vyas, S. Purswani and J. C. Gupta, Gonadotropin-releasing hormone/human chorionic gonadotropin β based recombinant antibodies and vaccines, *J. Reprod. Immunol.*, 2009, **83**(1–2), 158–163, DOI: [10.1016/j.jri.2009.08.008](https://doi.org/10.1016/j.jri.2009.08.008).
- 32 H. K. Vyas, R. Pal, R. Vishwakarma, N. K. Lohiya and G. P. Talwar, Selective killing of leukemia and lymphoma cells ectopically expressing HCG β by a conjugate of curcumin with an antibody against HCG β subunit, *Oncology*, 2009, **76**(2), 101–111, DOI: [10.1159/000188665](https://doi.org/10.1159/000188665).
- 33 H. Depypere, Y. Su, N. Dang, B. Poppe, F. Stanczyk, J. Janssens and J. Russo, Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers, *Eur. J. Cancer Prev.*, 2021, **30**(3), 195–203, DOI: [10.1097/CEJ.0000000000000664](https://doi.org/10.1097/CEJ.0000000000000664).
- 34 L. A. Cole, hCG, the wonder of today's science, *Reprod. Biol. Endocrinol.*, 2012, **10**, 1–18.

